CAR-T cell therapy - PersonGen BioTherapeutics
Alternative Names: LV-CAR - PersonGen BioTherapeutics; mRNA-CAR - PersonGen BioTherapeuticsLatest Information Update: 06 Sep 2024
At a glance
- Originator PersonGen Biotherapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; RNA
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Aug 2024 Preclinical trials in Cancer in China (Parenteral) prior to August 2024 (PersonGen BioTherapeutics pipeline, August 2024)